Showing 11-13 of 13 results for "".
- FDA Proposes Policy for New Competitive Generic Therapies Pathwayhttps://practicaldermatology.com/news/fda-proposes-policy-for-new-competitive-generic-therapies-pathway/2459896/The FDA has issued a new policy it says is intended to improve access and increase competition for drugs that lack generic competition. The new pathway for Competitive Generic Therapies (CGTs) creates a designation that can be granted to a company submitting an application for their generic drug …
- FDA: Pills Don't Replace Sunscreenhttps://practicaldermatology.com/news/fda-pills-dont-replace-sunscreen/2457749/The U.S. Food and Drug Administration (FDA) is cracking down on companies marketing supplements that claim to counter the effects of the sun's ultraviolet rays. These companies — marketing products called Advanced Skin Brightening Formula, Sunsafe Rx, Solaricare and Sunergetic — “are putting peopl…
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011…
- Previous
- Next